These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34757482)

  • 1. Novel pathological staging for patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by surgery.
    Oguma J; Ishiyama K; Kurita D; Kanematsu K; Fujii Y; Kubo K; Yamamoto S; Honma Y; Kato K; Daiko H
    Esophagus; 2022 Apr; 19(2):214-223. PubMed ID: 34757482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
    Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H
    Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposed modification of the eighth edition of the AJCC-ypTNM staging system of esophageal squamous cell cancer treated with neoadjuvant chemotherapy: Unification of the AJCC staging system and the Japanese classification.
    Oshikiri T; Goto H; Kato T; Sawada R; Harada H; Urakawa N; Hasegawa H; Kanaji S; Yamashita K; Matsuda T; Fujino Y; Tominaga M; Kakeji Y
    Eur J Surg Oncol; 2022 Aug; 48(8):1760-1767. PubMed ID: 35094909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
    Kitasaki N; Hamai Y; Emi M; Kurokawa T; Yoshikawa T; Hirohata R; Ohsawa M; Okada M
    In Vivo; 2022; 36(6):2852-2860. PubMed ID: 36309376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
    Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
    Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
    Wong IYH; Chung JCY; Zhang RQ; Gao X; Lam KO; Kwong DLW; Chao YK; Law SYK
    Ann Surg; 2022 Nov; 276(5):784-791. PubMed ID: 35876374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy.
    Kurokawa T; Hamai Y; Emi M; Ibuki Y; Yoshikawa T; Ohsawa M; Hirohata R; Okada M
    Anticancer Res; 2020 Aug; 40(8):4387-4394. PubMed ID: 32727767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphovascular Invasion as the Major Prognostic Factor in Node-Negative Esophageal Cancer After Primary Esophagectomy.
    Hsu CP; Chuang CY; Hsu PK; Chien LI; Lin CH; Yeh YC; Hsu HS; Wu YC
    J Gastrointest Surg; 2020 Jul; 24(7):1459-1468. PubMed ID: 31273552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival impact of the number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Jiang D; Liu XB; Xing WQ; Chen PN; Feng SK; Yan S; Lerut T; Sun HB
    Dis Esophagus; 2023 Apr; 36(5):. PubMed ID: 36385581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
    Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
    BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yun JK; Kim Y; Lee GD; Choi S; Kim YH; Kim DK; Park SI; Kim HR
    Cancer Med; 2022 Oct; 11(19):3623-3632. PubMed ID: 35434935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma.
    Cao XF; He XT; Ji L; Xiao J; Lv J
    Dis Esophagus; 2009; 22(6):477-81. PubMed ID: 19703071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and risk factors for early recurrence after esophagectomy following neoadjuvant chemotherapy for esophageal cancer.
    Kurogochi T; Honda M; Takahashi K; Okamura A; Imamura Y; Yamashita K; Kamiya S; Hayami M; Mine S; Watanabe M
    Surg Today; 2022 Apr; 52(4):660-667. PubMed ID: 34708307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and Validation of Lymphovascular Invasion as a Prognostic and Staging Factor in Node-Negative Esophageal Squamous Cell Carcinoma.
    Huang Q; Luo K; Chen C; Wang G; Jin J; Kong M; Li B; Liu Q; Li J; Rong T; Chen H; Zhang L; Chen Y; Zhu C; Zheng B; Wen J; Zheng Y; Tan Z; Xie X; Yang H; Fu J
    J Thorac Oncol; 2016 Apr; 11(4):583-92. PubMed ID: 26792626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nationwide validation of the prognostic impact of pathological response and the distribution of recurrence patterns in responders after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
    Matsuda S; Kitagawa Y; Kawakubo H; Okui J; Okamura A; Takemura R; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
    Esophagus; 2023 Apr; 20(2):205-214. PubMed ID: 36319809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
    Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
    Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
    [No Abstract]   [Full Text] [Related]  

  • 19. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer Control TNM staging system in patients with lower esophageal cancer undergoing neoadjuvant chemotherapy followed by surgery.
    Mehta SP; Jose P; Mirza A; Pritchard SA; Hayden JD; Grabsch HI
    Dis Esophagus; 2013; 26(2):182-8. PubMed ID: 22591020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.